This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1982 May;13(5):750-2.

doi: 10.1111/j.1365-2125.1982.tb01453.x.

Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers

P Dayer, A Kubli, A Kupfer, F Courvoisier, L Balant, J Fabre

PMID: 6123344
PMCID: PMC1402093
DOI: 10.1111/j.1365-2125.1982.tb01453.x

Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers

P Dayer et al. Br J Clin Pharmacol. 1982 May.

. 1982 May;13(5):750-2.

doi: 10.1111/j.1365-2125.1982.tb01453.x.

Authors

P Dayer, A Kubli, A Kupfer, F Courvoisier, L Balant, J Fabre

PMID: 6123344
PMCID: PMC1402093
DOI: 10.1111/j.1365-2125.1982.tb01453.x

No abstract available

PubMed Disclaimer

Similar articles

The genetic control of bufuralol metabolism in man.
Dayer P, Balant L, Courvoisier F, Kupfer A, Kubli A, Gorgia A, Fabre J. Dayer P, et al. Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):73-7. doi: 10.1007/BF03189547. Eur J Drug Metab Pharmacokinet. 1982. PMID: 6121708
The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T, Dayer P. Meyer UA, et al. Xenobiotica. 1986 May;16(5):449-64. doi: 10.3109/00498258609050251. Xenobiotica. 1986. PMID: 2874666
[Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].
Dayer P, Courvoisier F, Kupfer A, Balant-Gorgia A, Balant L, Fabre J. Dayer P, et al. Schweiz Med Wochenschr. 1983 Feb 26;113(8):295-7. Schweiz Med Wochenschr. 1983. PMID: 6133350 French.
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Lennard MS, Tucker GT, Woods HF. Lennard MS, et al. Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001. Clin Pharmacokinet. 1986. PMID: 2868819 Review.
Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s.
Narimatsu S, Takemi C, Kuramoto S, Tsuzuki D, Hichiya H, Tamagake K, Yamamoto S. Narimatsu S, et al. Chirality. 2003 May 5;15(4):333-9. doi: 10.1002/chir.10212. Chirality. 2003. PMID: 12666241 Review.

See all similar articles

Cited by

Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.
Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA, Wedlund PJ. Guttendorf RJ, et al. Br J Clin Pharmacol. 1990 Apr;29(4):373-80. doi: 10.1111/j.1365-2125.1990.tb03653.x. Br J Clin Pharmacol. 1990. PMID: 2328190 Free PMC article. Clinical Trial.
Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.
Dayer P, Leemann T, Marmy A, Rosenthaler J. Dayer P, et al. Eur J Clin Pharmacol. 1985;28(2):149-53. doi: 10.1007/BF00609683. Eur J Clin Pharmacol. 1985. PMID: 2859203
The genetic control of bufuralol metabolism in man.
Dayer P, Balant L, Courvoisier F, Kupfer A, Kubli A, Gorgia A, Fabre J. Dayer P, et al. Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):73-7. doi: 10.1007/BF03189547. Eur J Drug Metab Pharmacokinet. 1982. PMID: 6121708
Clinical significance of genetic influences on cardiovascular drug metabolism.
Arcavi L, Benowitz NL. Arcavi L, et al. Cardiovasc Drugs Ther. 1993 Jun;7(3):311-24. doi: 10.1007/BF00880154. Cardiovasc Drugs Ther. 1993. PMID: 8103355 Review.
Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Dayer P, Leemann T, Küpfer A, Kronbach T, Meyer UA. Dayer P, et al. Eur J Clin Pharmacol. 1986;31(3):313-8. doi: 10.1007/BF00981130. Eur J Clin Pharmacol. 1986. PMID: 2878813

See all "Cited by" articles

References

1. Biomed Mass Spectrom. 1976 Dec;3(6):281-5 - PubMed
1. Schweiz Med Wochenschr. 1976 Oct 9;106(41):1403-7 - PubMed
1. Lancet. 1977 Sep 17;2(8038):584-6 - PubMed
1. Schweiz Med Wochenschr. 1978 May 20;108(20):756-64 - PubMed
1. Br Med J. 1978 Sep 2;2(6138):655-7 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources